EKF opens for live chats at ENDO Online 2020

EKF Diagnostics, the global in vitro diagnostics company, announces that its online exhibition booth at this year’s ENDO Online 2020 will be open for live chats on its range of diagnostic products for glycemic monitoring and ketosis testing from June 10 to 17.

Organized by the Endocrine Society, ENDO Online 2020 runs from 8 – 20th June, featuring a combination of live and on-demand programming and its virtual Exhibit Hall. This gives researchers and clinicians access to the latest information within the field of endocrinology without having to leave their office. As the COVID-19 pandemic has canceled many meetings, making access to learning opportunities and new science challenging, visitors can register for free online access to ENDO Online 2020.

EKF’s booth (https://endoonline.endocrine.org/exhibitor-EKF) will allow visitors to learn about the Company’s line of diagnostic tests and analyzers used in glycemic monitoring and ketosis. These products are used in laboratories, hospitals, and clinics worldwide. Visitors can discuss their needs directly with EKF personnel in live chats during designated hall hours from 10 am to 12 pm (EDT) on June 10 – 13th and June 15—17th.

Key product highlights from EKF include the Lucica® Glycated Albumin-L manufactured by Asahi Kasei Pharma. This test is FDA-cleared for sale in the U.S. and sold exclusively by EKF as a specific intermediate glycemic control marker. It delivers a specific quantitative determination of glycated albumin (GA) in serum on compatible clinical chemistry analyzers with open channel capability. The Lucica® GA has been one of the world’s most widely used and published enzymatic GA methods.

EKF also offers multiple options for measuring Beta-Hydroxybutyrate (BHB), the main ketone body produced during diabetic ketoacidosis (DKA). Measuring the level of BHB is clinically helpful in diagnosing ketoacidosis earlier and monitoring the treatment results.

The LiquiColor® B-HB test features liquid, ‘ready to use’ reagents. It is intended to quantitatively measure BHB with serum or plasma on compatible clinical chemistry analyzers with open-channel capability. LiquiColor® B-HB is used in more than 1,300 laboratories in the U.S.

EKF’s new STAT-Site® WB, a point-of-care Beta-Hydroxybutyrate and Glucose testing device, will also be introduced. The STAT-Site® WB dual-analyte measurement system is CLIA-waived, easy to use, and provides reliable quantitative results in 5-10 seconds. It is intended for whole blood multiple-patient use in professional healthcare settings as an aid to monitoring the effectiveness of a diabetes control program.